Further studies have demonstrated its effects on altered coagulation tests, including prolonged activated partial thromboplastin times, reduced antithrombin III (AT III) activity, and increased levels of D-Dimer and fibrinogen degradation products in aCL-positive cerebral infarction patients. Here, SERPINC1 is linked to brain infarction.